SCHEMBL5675845

SCHEMBL5675845

CC(C)(C)P(C1=CC=CCC1c1ccccc1)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13645456 0.68 CYP19A1 (0.32)
SCHEMBL13523395 0.68 SLC6A2 (0.36)
SCHEMBL21416522 0.68 CFTR (0.34)
SCHEMBL5545795 0.67 CFTR (0.44)
Hydrochloric Acid SCHEMBL4688611 0.65 TSHR (0.34)
SCHEMBL5268966 0.65 HDAC4 (0.35)
SCHEMBL5595914 0.64 CFTR (0.33)
SCHEMBL4965023 0.63 CA2 (0.36)
Lithium SCHEMBL5574358 0.63 CFTR (0.32)
SCHEMBL4794294 0.62 L3MBTL1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636160-A4 NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS AUSPEX PHARMACEUTICALS (US) 2006-09-27 EP disclosed
EP-1636160-A2 NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS Auspex Pharmaceuticals (US) 2006-03-22 EP disclosed
WO-2005000233-A2 NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS AUSPEX PHARMACEUTICALS (US) 2005-01-06 WO disclosed